SNTI SNTI
Company Profile ↓Company Overview
SNTI (SNTI) is a publicly traded company listed on with a market capitalization of $11.43M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Recent Developments
- 5-Year Trend Long-term compounding — revenue CAGR -81.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -81.15% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -77.80% |
| 6 Months: | -61.94% |
| 3 Months: | -60.90% |
| 1 Month: | -63.07% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)26.87 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -81.2% CAGR over 5 years.
- Trading 84.4% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 778.00K | 926.00K | 854.00K | 1.11M | 1.52M | - | 1.04M | 687.00K | 255.00K | - | 0 | 0 | 0 | - | 0 | 0 | 0 | 22.00K | 16.00K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 16.40M | 16.80M | 16.95M | 13.61M | 11.51M |
| Operating Income | - | -9.00M | -11.42M | -11.76M | -21.77M | -14.75M | - | -14.96M | -15.19M | -43.88M | - | -16.30M | -13.36M | -15.21M | - | -16.40M | -16.80M | -16.95M | -13.58M | -11.50M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -15.47M | -14.78M | -16.27M | -12.69M | -10.81M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -14.11M | -14.73M | -18.13M | -14.47M | -4.22M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -21.00M | -12.01M | -11.41M | -11.81M | -11.55M | -16.64M | -58.21M | -18.72M | -18.70M | -14.92M | -71.06M | -12.11M | -11.20M | -28.87M | - | -14.11M | -14.73M | -18.13M | -14.47M | -4.22M |
| Diluted EPS | - | -4.13 | -3.90 | -3.72 | -0.86 | -0.38 | - | -0.42 | -4.22 | -3.36 | - | -2.65 | -2.45 | -6.31 | - | -1.41 | -0.56 | -0.69 | -0.53 | -0.14 |
| R&D Expense | - | 5.24M | 5.41M | 7.60M | 9.25M | 6.52M | - | 7.06M | 6.88M | 9.09M | - | 8.78M | 9.15M | 8.65M | - | 9.28M | 10.03M | 10.52M | - | 5.28M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 3.29M | 1.98M | 0 | 22.00K |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 65.37M | 68.74M | 60.73M | 63.75M |
| Operating Income | - | -62.08M | -66.77M | -60.73M | -63.73M |
| EBITDA | - | -58.16M | -61.34M | -56.89M | -60.09M |
| Interest Expense | - | - | - | - | - |
| Pretax Income | - | -49.66M | -83.41M | -52.79M | -61.44M |
| Tax Provision | - | - | - | - | - |
| Net Income | - | -58.21M | -71.06M | -52.79M | -61.44M |
| Diluted EPS | - | -22.30 | -16.01 | -12.03 | -2.73 |
| R&D Expense | 21.96M | 28.14M | 32.15M | 34.36M | 37.59M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2020 | Feb 2021 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | 180.79M | 119.48M | 97.84M | 51.22M |
| Current Assets | - | - | - | 102.58M | 71.20M | 58.96M | 23.27M |
| Cash & Equivalents | - | 0 | - | 57.62M | 35.93M | 48.28M | 16.42M |
| Inventory | - | - | - | - | - | - | - |
| Receivables | - | - | - | 626.00K | 112.00K | 159.00K | 323.00K |
| Total Liabilities | - | - | - | 53.53M | 52.57M | 72.19M | 45.63M |
| Current Liabilities | - | - | - | 18.05M | 12.67M | 13.15M | 13.97M |
| Long Term Debt | - | - | - | - | - | - | - |
| Total Debt | - | - | - | 37.09M | 37.67M | 33.54M | 28.89M |
| Total Equity | -58.71M | 0 | - | 127.26M | 66.91M | 25.65M | 5.59M |
| Shares Outstanding | - | - | - | 4.41M | 4.57M | 4.83M | 30.88M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -34.90M | -52.40M | -41.40M | -43.44M |
| Investing Cash Flow | - | -81.96M | 30.08M | 34.00K | -184.00K |
| Financing Cash Flow | - | 118.55M | 779.00K | 53.73M | 11.76M |
| Capital Expenditure | - | -41.37M | -12.04M | -26.00K | -196.00K |
| Free Cash Flow | - | -76.27M | -64.43M | -41.42M | -43.64M |
| Net Change in Cash | - | 1.70M | -21.54M | 12.37M | -31.87M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | -1,889.3% | -3,375.4% | - | -289,668.2% |
| Net Margin % | - | -1,771.5% | -3,592.4% | - | -279,263.6% |
| ROE % | - | -45.7% | -106.2% | -205.8% | -1,099.3% |
| ROCE % | - | -38.1% | -62.5% | -71.7% | -171.1% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SNTI
Senti Biosciences Holdings Inc. (SNTI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
<a href="https://news.google.com/rss/articles/CBMiTkFVX3lxTE5kN3ZBN3pvX1pBSUc2eWdveFF4NG1jZGNxcTdrNWZyd3FqVm1QS2RlcW5iRkZ1OF9BTGtKTzFBX0I2TngybzJwbHU4a3ZKUQ?oc=5" target="_blank">Senti Biosciences Holdings Inc. (SNTI) Stock Price | Live Quo…
SNTI Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE1UUFY0UDBBSFUwY3R6N0NYOGRzMGxuMk9aQUhRZ0lpenNFRW1wVFQ5bnZUcVh5M1VIREdhZXZLOHpSVFZFRzFPU0ZOZ3FOb1ctV3BVNEE4ZC1QeDNoNGJFbmt4MW9uVFdiSVdPXy1RY0E4TG53cDhJa2pB?oc=5" target="_blank">SNT…
Senti Biosciences Holdings, Inc. SEC Filing (Jul 21, 2026) | SNTI ARS - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxNWHMtdS12NEZ1UGl3SThuUURjbmZreDVybklnZjFfd05TU2ZGblhKX2p4ZDZXLVc0OGlMWDNwRFFqNF8wZ0UtN0tqNG5QLWtCWmNGdloySkZvalpvTDJTWU9ra2cyYXdlRjFnWHE1X2JTUkpZMnNvODEzUy0zOUk3UEFpRFdzemh3ckJpTG…
SNTI|Senti Biosciences Inc|Price:0.341|Chg%:-0.020 - TradingKey
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE9LT3VLRUxfWmZFdzhHMGZTNmtZdl9yV3RidlpjSHRkUmxTVU9XSDl0SlRtUjFrWk9Da2pfQURaOXJQVE1EUzUwVTQxNjFSdXQtb0czb2l4YmVYN1lidGg1Z21ZczNTWjhWU0kxaGdB?oc=5" target="_blank">SNTI|Senti Bioscien…
SNTI Should I Buy - Intellectia AI
<a href="https://news.google.com/rss/articles/CBMiXkFVX3lxTE9TdmEyb3RmUElvX1pnVlJ6YXd4cVFNakZhU3VIUWxudWVhNU9GVG5DODBCZEt3NDFrVFoybzI0Sy1IT1cxc3NGTHVWMjlha2Q1MFY5d0pJSWs3NkEtZXc?oc=5" target="_blank">SNTI Should I Buy</a> <font c…
Senti Biosciences Secures Up to $40 Million Financing and FDA Endorsement for SENTI-202 in Relapsed/Refractory Acute Myeloid Leukemia - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMi_AFBVV95cUxOMHJXMTgtWk45MDN6aE5xU0pkN25LeGdDemFYbVEyRlVKcEh6Z0JLUHk2M2VQNk1mUnpqbk5oaUhaRTc3cU9lRnVUR3UwM25ZMTh4U0dsUDdwd0dCVV9MSmZ0WDFPbDhyay1IMGcyc1hhMG5scXQtU0lOQkxtREhNbDdkUTlYNHdISGdKRW…
SNTI — Frequently Asked Questions
What is the current share price of SNTI?
As of 2026-08-05 17:25 PDT, SNTI trades at $0.37 on NASDAQ/NYSE. Its 52-week range is $0.34 to $2.39.
What is the market capitalisation of SNTI?
SNTI has a market capitalisation of $11.43M on NASDAQ/NYSE.
What is the P/E ratio of SNTI?
SNTI trades at a trailing price-to-earnings (P/E) ratio of -0.14. Its price-to-book (P/B) ratio is 2.04.
Is SNTI a good stock to buy?
This page provides a data-driven analysis of SNTI, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.